- Home
- BCTX vs ISDR Comparison
BCTX vs ISDR Comparison
Compare BCTX & ISDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- ISDR
- Stock Information
- Founded
- BCTX 2014
- ISDR 1988
- Country
- BCTX Canada
- ISDR United States
- Employees
- BCTX N/A
- ISDR N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- ISDR Publishing
- Sector
- BCTX Health Care
- ISDR Consumer Discretionary
- Exchange
- BCTX Nasdaq
- ISDR Nasdaq
- Market Cap
- BCTX 34.6M
- ISDR 35.0M
- IPO Year
- BCTX N/A
- ISDR N/A
- Fundamental
- Price
- BCTX $0.41
- ISDR $9.22
- Analyst Decision
- BCTX Strong Buy
- ISDR
- Analyst Count
- BCTX 1
- ISDR 0
- Target Price
- BCTX $15.00
- ISDR N/A
- AVG Volume (30 Days)
- BCTX 977.6K
- ISDR 15.0K
- Earning Date
- BCTX 03-17-2025
- ISDR 03-06-2025
- Dividend Yield
- BCTX N/A
- ISDR N/A
- EPS Growth
- BCTX N/A
- ISDR N/A
- EPS
- BCTX N/A
- ISDR N/A
- Revenue
- BCTX N/A
- ISDR $29,141,000.00
- Revenue This Year
- BCTX N/A
- ISDR N/A
- Revenue Next Year
- BCTX N/A
- ISDR N/A
- P/E Ratio
- BCTX N/A
- ISDR N/A
- Revenue Growth
- BCTX N/A
- ISDR N/A
- 52 Week Low
- BCTX $0.37
- ISDR $7.61
- 52 Week High
- BCTX $4.37
- ISDR $16.92
- Technical
- Relative Strength Index (RSI)
- BCTX 36.36
- ISDR 51.12
- Support Level
- BCTX $0.38
- ISDR $8.54
- Resistance Level
- BCTX $0.42
- ISDR $9.60
- Average True Range (ATR)
- BCTX 0.05
- ISDR 0.47
- MACD
- BCTX 0.00
- ISDR 0.09
- Stochastic Oscillator
- BCTX 12.86
- ISDR 71.64
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About ISDR Issuer Direct Corporation
Issuer Direct Corp is a communications and compliance company. It focuses on the needs of corporate issuers. It provides disclosure management solutions, shareholder communications tools, and cloud-based compliance technologies. Its customers include public and private companies, mutual funds, law firms, brokerage firms, investment banks, individuals, and other institutions. Its products include PR solutions, IR solutions, Compliance, and Event management software.